We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Smith+Nephew's (SNN) PICO sNPWT Study Outcome Encouraging
Read MoreHide Full Article
Smith+Nephew (SNN - Free Report) recently announced favorable study outcome of a new publication evaluating its PICO Single Use Negative Pressure Wound Therapy System (sNPWT) indicated for use in closed surgical incisions. The study shows that the use of PICO sNPWT reduces the chances of surgical site complications.
This development highlights the company’s commitment toward strengthening its Global Sports Medicine business segment.
PICO sNPWT at a Glance
PICO snPWT is completely portable, which includes the AIRLOCK technology for consistent delivery of Negative Pressure Wound Therapy. This device is effective in the treatment of surgical, chronic and acute wounds.
Study Outcomes
The methodical review and meta-analysis include 29 studies based on the outcomes of 5,614 patients. It shows significant benefits for patients across different surgical specialties, including orthopaedic, obstetric, cardiothoracic, colorectal, vascular and breast surgery, from a wide geographical distribution by using PICO sNPWT on closed surgical incisions.
The study highlighted PICO sNPWT reduces the probability of surgical site infections (SSIs) by 63%, the chances of seroma by 77% and of dehiscence by 30%.
The new meta-analysis adds significant evidence supporting PICO therapy for prevention of post-operative surgical site complications and also provides significant insights for effective clinical management for prevention of SSIs.
Notably, PICO sNPWT has a strong evidence base with almost 137 published papers, which include medical technology guidance from the UK National Institute for Health and Care Excellence (NICE), supporting the adoption of PICO sNPWT as it provides better outcomes along with cost effectiveness compared to standard care by helping to prevent SSCs in high-risk patients.
Industry Prospects
Per a report by MarketsandMarkets, the global negative pressure wound therapy market was valued at $2,113.6 million in 2018 and is expected to reach $2,724.2 million by 2023, at a CAGR of 5.2%. Rising prevalence of diabetes, increasing spending on chronic and surgical wounds, government initiatives to prevent SSIs, and high rate of cesarean sections in elderly mothers leading to increasing post-operative use of NPWT devices are driving the market.
Recent Developments
This month, Smith+Nephew collaborated with Hall of Fame Health to utilize the company’s digital health portfolio for former National Football League players seeking joint replacement through a quality care network. The partnership is intended to supplement other health care options for ex-players, such as those available through the National Football League and its Player Care Foundation, which assists NFL retirees.
Earlier this month, Smith+Nephew announced the acquisition of the Extremity Orthopedics business of Integra LifeSciences Holdings Corporation for $240 million. The buyout will strengthen Smith+Nephew’s extremities business by adding a combination of a focused sales channel, complementary shoulder replacement and upper and lower extremities portfolio, and a new product pipeline.
Price Performance
Over the past three months, shares of the company have gained 22.5% compared with the industry’s growth of 12.3%.
Zacks Rank and Key Picks
Currently, Smith+Nephew carries a Zacks Rank #3 (Hold).
Myomo has a projected long-term earnings growth rate of 48%.
Meridian Bioscience has a projected long-term earnings growth rate of 16%.
OraSure Technologies has an estimated long-term earnings growth rate of 629%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Smith+Nephew's (SNN) PICO sNPWT Study Outcome Encouraging
Smith+Nephew (SNN - Free Report) recently announced favorable study outcome of a new publication evaluating its PICO Single Use Negative Pressure Wound Therapy System (sNPWT) indicated for use in closed surgical incisions. The study shows that the use of PICO sNPWT reduces the chances of surgical site complications.
This development highlights the company’s commitment toward strengthening its Global Sports Medicine business segment.
PICO sNPWT at a Glance
PICO snPWT is completely portable, which includes the AIRLOCK technology for consistent delivery of Negative Pressure Wound Therapy. This device is effective in the treatment of surgical, chronic and acute wounds.
Study Outcomes
The methodical review and meta-analysis include 29 studies based on the outcomes of 5,614 patients. It shows significant benefits for patients across different surgical specialties, including orthopaedic, obstetric, cardiothoracic, colorectal, vascular and breast surgery, from a wide geographical distribution by using PICO sNPWT on closed surgical incisions.
The study highlighted PICO sNPWT reduces the probability of surgical site infections (SSIs) by 63%, the chances of seroma by 77% and of dehiscence by 30%.
The new meta-analysis adds significant evidence supporting PICO therapy for prevention of post-operative surgical site complications and also provides significant insights for effective clinical management for prevention of SSIs.
Notably, PICO sNPWT has a strong evidence base with almost 137 published papers, which include medical technology guidance from the UK National Institute for Health and Care Excellence (NICE), supporting the adoption of PICO sNPWT as it provides better outcomes along with cost effectiveness compared to standard care by helping to prevent SSCs in high-risk patients.
Industry Prospects
Per a report by MarketsandMarkets, the global negative pressure wound therapy market was valued at $2,113.6 million in 2018 and is expected to reach $2,724.2 million by 2023, at a CAGR of 5.2%. Rising prevalence of diabetes, increasing spending on chronic and surgical wounds, government initiatives to prevent SSIs, and high rate of cesarean sections in elderly mothers leading to increasing post-operative use of NPWT devices are driving the market.
Recent Developments
This month, Smith+Nephew collaborated with Hall of Fame Health to utilize the company’s digital health portfolio for former National Football League players seeking joint replacement through a quality care network. The partnership is intended to supplement other health care options for ex-players, such as those available through the National Football League and its Player Care Foundation, which assists NFL retirees.
Earlier this month, Smith+Nephew announced the acquisition of the Extremity Orthopedics business of Integra LifeSciences Holdings Corporation for $240 million. The buyout will strengthen Smith+Nephew’s extremities business by adding a combination of a focused sales channel, complementary shoulder replacement and upper and lower extremities portfolio, and a new product pipeline.
Price Performance
Over the past three months, shares of the company have gained 22.5% compared with the industry’s growth of 12.3%.
Zacks Rank and Key Picks
Currently, Smith+Nephew carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space include Myomo, Inc. (MYO - Free Report) , Meridian Bioscience, Inc. and OraSure Technologies, Inc. (OSUR - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.
Myomo has a projected long-term earnings growth rate of 48%.
Meridian Bioscience has a projected long-term earnings growth rate of 16%.
OraSure Technologies has an estimated long-term earnings growth rate of 629%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot stocks we're targeting >>